Sanofi's Lyxumia added to Lantus meets Phase III trial endpoint
This article was originally published in Scrip
Executive Summary
The life cycle management of the Sanofi blockbuster diabetes drug Lantus has become clearer after the French multinational pharma revealed that its investigational, once-daily GLP-1 agonist, Lyxumia (lixisenatide) met its primary endpoint when added to the company’s top-selling product Lantus (insulin glargine) and metformin as a treatment of type 2 diabetes. Sanofi has reported that the combination achieved the primary efficacy endpoint of significantly reducing HbA1c from baseline to week 24 versus placebo in a Phase III trial dubbed GetGoal Duo 1. In the trial, HbA1c <7%>